ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

NXL Nexalin Technologies Inc

1.44
0.055 (3.97%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Nexalin Technologies Inc NXL NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.055 3.97% 1.44 17:26:29
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
1.45 1.41 1.54 1.44 1.385
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
25/4/202409:44GLOBENexalin Technology Regains Compliance with Nasdaq Continued..
09/4/202407:30GLOBENexalin Technology Accelerates Manufacturing of its HALO™..
04/4/202412:00GLOBENexalin Technology Awarded Key Patent Related to its Gen-3..
02/4/202407:30GLOBENexalin Technology Announces the Appointment of Government..
28/3/202407:30GLOBENexalin Technology Announces Positive Results of Clinical..
14/3/202407:30GLOBENexalin Technology Commences Sales of Gen-2 Neurostimulation..
13/3/202407:30GLOBENexalin Technology Announces Poster Presentation at “State..
08/2/202407:30GLOBENexalin Technology Announces Regulatory Approval in Oman for..
23/1/202407:30GLOBENexalin Technology Awarded Key Patent Related to its..
11/1/202407:30GLOBENexalin Technology Unveils Next-Generation HALO™ Clarity
18/12/202307:30GLOBENexalin Technology Reports Significant Positive Results of..
13/11/202315:38EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202313:38EDGAR2Form 8-K - Current report
25/10/202307:30GLOBENexalin Technology Announces Formation of New Military &..
16/10/202307:30GLOBENexalin Technology Announces Publication of Groundbreaking..
05/10/202311:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/10/202311:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/10/202311:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/9/202315:18EDGAR2Form 8-K - Current report
10/8/202314:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202307:30GLOBENexalin Technology Reports Results of Clinical Study..
03/8/202307:30GLOBENexalin’s CEO Mark White to be Interviewed Live on “The Big..
26/7/202307:30GLOBENexalin Technology Announces New Public Sector Division to..
10/7/202307:30GLOBENexalin Technology Announces Abstract Accepted for..
30/6/202314:15EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
01/6/202307:30GLOBENexalin Technology, Inc. and Wider Come Limited Announce..

Su Consulta Reciente

Delayed Upgrade Clock